Your browser doesn't support javascript.
loading
Technetium-99m-labeled rituximab for use as a specific tracer of sentinel lymph node biopsy: a translational research study.
Wang, Xuejuan; Yang, Zhi; Lin, Baohe; Zhang, Yan; Zhai, Shizhen; Zhao, Qichao; Xie, Qing; Liu, Fei; Han, Xuedi; Li, Jinfeng; Ouyang, Tao.
Afiliação
  • Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Yang Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Lin B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Zhang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Zhai S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Zhao Q; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Xie Q; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Liu F; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Han X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing 100142, P. R. China.
  • Li J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, P. R. China.
  • Ouyang T; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, P. R. China.
Oncotarget ; 7(25): 38810-38821, 2016 Jun 21.
Article em En | MEDLINE | ID: mdl-27246977

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Compostos de Organotecnécio / Antígenos CD20 / Biópsia de Linfonodo Sentinela / Anticorpos Monoclonais Murinos / Rituximab Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Compostos de Organotecnécio / Antígenos CD20 / Biópsia de Linfonodo Sentinela / Anticorpos Monoclonais Murinos / Rituximab Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article